Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1701034 | 0.87 | ALDH1A1 (0.34) | ALDH1A1HPGD | |
| SCHEMBL571449 | 0.77 | NPC1 (0.34) | LMNAKDM4E | |
| SCHEMBL6908493 | 0.70 | MAPT (0.39) | MAPTLMNAKDM4EALDH1A1HPGD | |
| SCHEMBL4516047 | 0.64 | CES2 (0.39) | KDM4E | |
| SCHEMBL2116183 | 0.64 | — | — | |
| SCHEMBL1187892 | 0.64 | — | — | |
| SCHEMBL3605686 | 0.64 | — | — | |
| SCHEMBL31604210 | 0.64 | — | — | |
| SCHEMBL7532803 | 0.64 | — | — | |
| Benzene SCHEMBL26120991 | 0.64 | MAPT (0.38) | MAPTLMNAKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116925023-A | Improved synthesis of 2-perfluoroalkyl-4H-pyran-4-one derivatives | 江苏桐孚高新材料有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-3548466-B1 | PROCESS FOR PREPARATION OF INTERMEDIATE OF PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2022-01-12 | — | — | EP | disclosed |
| US-10961248-B2 | Pesticidally active heterocyclic derivatives with sulfur containing substituents | SYNGENTA PARTICIPATIONS AG (CH) | 2021-03-30 | — | — | US | disclosed |
| US-20190322675-A1 | Pesticidally Active Heterocyclic Derivatives with Sulfer Containing Substituents | SYNGENTA PARTICIPATIONS AG (CH) | 2019-10-24 | — | — | US | disclosed |
| WO-2018099812-A1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2018-06-07 | — | — | WO | disclosed |
| EP-2948452-B1 | 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-08-09 | — | — | EP | disclosed |
| EP-2948452-B1 | 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-08-09 | — | — | EP | disclosed |
| US-9708330-B2 | 2,3-dihydroimidazol[1,2-C]pyrimidin-5(1-H)-one based ipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-18 | — | — | US | disclosed |
| US-9708330-B2 | 2,3-dihydroimidazol[1,2-C]pyrimidin-5(1-H)-one based ipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-18 | — | — | US | disclosed |
| US-9708330-B2 | 2,3-dihydroimidazol[1,2-C]pyrimidin-5(1-H)-one based ipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-18 | — | — | US | disclosed |
| US-8716487-B2 | Process for preparing 4-hydroxypyridines | BASF SE (DE) | 2014-05-06 | — | — | US | disclosed |
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2585436-A1 | PROCESS FOR PREPARING 4-HYDROXYPYRIDINES | BASF SE (DE) | 2013-05-01 | — | — | EP | disclosed |
| US-20130096312-A1 | Process for Preparing 4-hydroxypyridines | BASF SE (DE) | 2013-04-18 | — | — | US | disclosed |
| WO-2013013503-A1 | 2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013013503-A1 | 2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2011161612-A1 | PROCESS FOR PREPARING 4-HYDROXYPYRIDINES | BASF SE (DE) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096312-A1 | Process for Preparing 4-hydroxypyridines | QDPR, HRH4, CYP4B1 | MAPT 4407/4885LMNA 3060/4885KDM4E 768/4885 |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | MAPT 971/4885LMNA 1280/4885KDM4E 4592/4885 |
| US-10961248-B2 | Pesticidally active heterocyclic derivatives with sulfur containing substituents | DDT, ACHE, SQOR | MAPT 342/4885LMNA 4508/4885KDM4E 3259/4885 |
| US-20190322675-A1 | Pesticidally Active Heterocyclic Derivatives with Sulfer Containing Substituents | DDT, ACHE, SQOR | MAPT 1277/4885LMNA 3830/4885KDM4E 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.